Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Controversy Regarding HCV Treatment and HCC Recurrence

    Contains 1 Component(s) Recorded On: 03/08/2017

    Webinar hosted by the Hepatobiliary Neoplasia Special Interest group on March 8, 2017.

    This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.

    Michael D. Leise (Moderator)

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Amit G. Singal

    Dr. Singal completed his GI and transplant hepatology fellowships at the University of Michigan and is currently an Associate Professor of Medicine at UT Southwestern Medical Center in Dallas. He serves as Clinical Chief of Hepatology and Medical Director of the UT Southwestern and Parkland Memorial Liver Tumor programs. He has over 75 peer-reviewed publications, with the majority examining the hepatocellular carcinoma screening process, from risk assessment to early detection to treatment. 

  • Portal Vein Thrombosis in Cirrhosis: Causes and Consequences

    Contains 1 Component(s) Recorded On: 02/28/2017

    Webinar hosted by the Portal Hypertension Special Interest group on February 28, 2017.

    This webinar will focus on the concept of coagulation in cirrhosis; pathophysiology, concept of a rebalanced coagulation state in cirrhosis and the consequences such as portal vein thrombosis. The management of PVT will be discussed.

    Andres Cardenas (Moderator)

    Dr. Andrés Cárdenas is currently a Consultant and Clinical Professor of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and University of Barcelona. During his residency in Internal Medicine at Boston University Medical Center, he became interested in advanced liver disease, further pursuing a Research Fellowship in Hepatology for 2 years at Hospital Clinic and University of Barcelona in Spain. He returned to Harvard Medical School and BIDMC for his Clinical Fellowship in Gastroenterology and Hepatology. Dr. Cárdenas is Board Certified in Internal Medicine, Gastroenterology and Hepatology by the American Board of Internal Medicine. His main expertise and research interests are complications of cirrhosis, interventional procedures in patients with cirrhosis and portal hypertension and biliary complications in liver transplant recipients.

    Cristina Ripoll (Moderator)

    Dr. Cristina Ripoll is currently an attending physician in the gastroenterology division of the internal medicine I department of the Martin- Luther University Halle Wittenberg, Germany. She did her GI and hepatology and transplant training in the Gregorio Marañón Hospital in Madrid, Spain. She did a post-doctoral fellowship at Yale University with Prof. Groszmann and Prof. Garcia-Tsao. Her main research interests are complications of cirrhosis and portal hypertension. She is currently the secretary of the portal hypertension SIG. 

    Stephen H. Caldwell

    Dr. Stephen Caldwell is a hepatologist specializing in a nonalcoholic steatohepatitis (NASH), including its relationship to so-called cryptogenic cirrhosis, ethnic and familial relationships and the role of mitochondrial dysfunction in the disease. He and his colleagues pioneered work on cellular ballooning and the role of small fat droplets in NASH and have also worked extensively with cyanoacrylates in the treatment of gastric variceal bleeding. He is overseeing a number of treatment trials for NASH and related liver fibrosis and is closely involved with a network of physicians and scientists working with coagulation disorders in liver disease. In 1992, he joined the faculty at UVA, helping to develop the hepatology program. Now a professor of medicine in the Division of Gastroenterology and Hepatology at UVA, Dr. Caldwell is board-certified in internal medicine and gastroenterology.

    Juan C. Garcia-Pagan

    Juan Carlos Garcia-Pagán is a Senior consultant in Hepatology and Head of the Hepatic Hemodynamic section at the Hospital Clinic in Barcelona, Spain and Associate Professor at the University of Barcelona.

    He is currently sharing its clinical activity in the hospital with its clinical and basic research at the Institut de Investigacións Biomediques August Pi i Sunyer (IDIBAPS) and is also member of the Centro para Investigación Biomédica en Red de enfermedades hepaticas y digestivas (CIBEREHD).  The main research of Interest are: Pathophysiology and treatment of portal hypertension in cirrhosis and of vascular disorders of the liver. He is currently the chair of the EASL-VALDIG (Vascular liver disease group) .

  • Leon Schiff State-of-the-Art Lecture: Elimination of Hepatitis B: Is it possible?

    Product not yet rated Contains 1 Component(s) Recorded On: 11/15/2016

    AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2016.

    This lecture will provide a vision for the global elimination of hepatitis B (HBV) and strategies to reach that goal by examining the burden of hepatitis B infection and the disparity in prevalence across different parts of the world. Programs preventing hepatitis B infection, available treatment options in chronic hepatitis B, their limitations and novel therapies will also be discussed.

    Anna S. Lok

  • AASLD-APASL Symposium: Portal Hypertension

    Product not yet rated Contains 5 Component(s) Recorded On: 11/14/2016

    AASLD's AASLD-APASL Symposium presented at The Liver Meeting® 2016.

    The symposium will provide a broad overview on the diversity of portal hypertension in the Western World and in the Asia Pacific Region. Experts will discuss the presentation, diagnosis, and management of the consequences of portal hypertension, and will benefit all health care professionals engaged in encountering these patients in their clinical practice.

    K. Rajender Reddy

    Florence Wong

    Shiv K. Sarin

    Theo Heller

    Dr. Heller is a senior clinical investigator at the National Institutes of Health where he heads the Translational Hepatology Section. His research focuses on liver disease progression with a particular focus on non-cirrhotic portal hypertension as a model for all patients with portal hypertension. He is focused on enhancing the clinical care of patients with portal hypertension while elucidating mechanisms that underlie the development of portal hypertension due to any etiology. His research encompasses translational and clinical techniques with the ultimate aim of ensuring superb outcomes for patients with liver disease.

     

    Hitoshi Maruyama

  • 2016 Advances for Practitioners

    Contains 3 Component(s) Recorded On: 11/14/2016

    AASLD's Advances for Practitioners presented at The Liver Meeting® 2016.

    This program will provide trainees and practitioners with a careful review of highly impactful and clinically relevant papers in the management of alcoholic liver disease and NAFLD. Learn the caveats associated with the design, application and final message of key clinical studies, and identify the areas of that need further study. A special focus on emerging trends in the field and how these may impact the clinical management of alcoholic liver disease and BAFLD in coming years will be discussed.

    Philippe Mathurin

    Brent A. Tetri

    Christopher P. Day

  • Clinical Research Workshop

    Product not yet rated Contains 3 Component(s) Recorded On: 11/11/2016

    AASLD's Clinical Research Workshop presented at The Liver Meeting® 2016.

    This program will address the various designs used in patient-oriented research, including the strengths and limitations to each approach as well as the impact each technique has had on the study and care of patients with liver disease. In addition, approaches to obtaining funding for such research, as well as the development and use of quality measures for the care of patients with chronic liver disease will be discussed. Participants will have the opportunity to obtain more "hands-on" experience and direct feedback from experienced investigators during a series of dynamic and interactive breakout sessions.

    Zobair M. Younossi

    Fasiha Kanwal

    David R. Nelson

  • Public Health SIG: Population Health Management of Cirrhosis

    Contains 4 Component(s) Recorded On: 11/11/2016

    AASLD's Public Health SIG presented at The Liver Meeting® 2016.

    This program is intended to explore current and novel health care delivery approaches and strategies for managing populations affected by cirrhosis and portal hypertension. In contrast to disease-based symposium focused on novel diagnostic and treatment approaches, this program intends to focus on current and evolving approaches inspired by delivery system reform to ensure that high quality, patient-centered, and resource efficien medical care is delivered to large segments of patients with advanced liver disease. The emphasis of this program is on clinical knowledge.

    Michael Volk

    Brett E. Fortune

    Dr. Brett E. Fortune, MD, MSc, is a Transplant Hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation. His research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

    Paolo Angeli

    Fasiha Kanwal

  • New Concepts and Insights Into HBV Immunology

    Product not yet rated Contains 1 Component(s) Recorded On: 10/11/2016

    Webinar hosted by the Hepatitis B Special Interest group on October 11, 2016.

    This webinar will review the current state of the understanding of the immune response to hepatitis b (HBV). Two experts and one moderator will guide providers through an understanding of the HBV immune interactions that can help providers understand and help explain HBV infections, guide patient management and help embrace new therapies.

    Robert G. Gish (Moderator)

    Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.

    Antonio Bertoletti

    Dr. Antonio Bertoletti is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He began working in viral hepatitis as a medical student at the University of Parma (Italy). He continued his research work at the Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist and then worked at the University College of London (UK) (1997-2006) before moving to Singapore where he is now Professor at the Emerging Viral Disease Program at Duke-NUS Medical School. His current research is focus on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and HBV-related HCC.

    Kyong-Mi Chang

    Dr. Kyong-Mi Chang is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).

  • Management of Bleeding Fundal and Ectopic Varices – TIPS, BRTO, and Embolization

    Product not yet rated Contains 1 Component(s) Recorded On: 10/06/2016

    Webinar hosted by the Portal Hypertension Special Interest group on October 6, 2016.

    The evidence to support therapeutic decisions in patients with cirrhosis and fundal and ectopic varices is scarce, and treatment is controversial. In addition, since these varices are infrequent, clinicians have limited experience and knowledge of the therapeutic options. This webinar is aimed at providing an update on the treatment of patients with cirrhosis who are bleeding from fundal and ectopic varices, by providing the perspective of an expert clinician and an interventional radiologist, both North American leaders in the field.

    Guadalupe Garcia-Tsao (Moderator)

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Jonel Trebicka (Moderator)

    Dr. Jonel Trebicka is head of the Laboratory for Liver Fibrosis and Portal Hypertension, as well as the TIPS-Outpatient Clinic at the University Hospital Bonn, Germany. He is also an adjunct professor in gastroenterology and hepatology in Odense, Denmark. Dr. Trebicka is a member of the editorial board of American Journal of Physiology: Gastrointestinal and Liver Physiology, Scientific Reports and Journal of Hepatology, as well as in the Steering Committee of VALDIG-Consortium, Baveno-Cooperation and EF-CLIF. He was a faculty member at the BAVENO VI Consensus-Conference.

    Thomas D. Boyer

    Dr. Thomas D. Boyer is currently Professor of Medicine and Director of the Liver Research Institute at the University of Arizona School of Medicine in Tucson, Arizona. He has a longstanding interest in the complications of portal hypertension including bleeding varices, ascites, and hepatorenal syndrome. Dr. Boyer has published a number of papers in each of these areas of interest.

    Wael E. Saad

    Dr. Saad is a Physician of 20 years and is internationally recognized for liver disease including liver transplantation, hepatobiliary disease and portal hypertension. He has over 240 publications and over 70 book chapters and is an author of 4 books. He completed his residency at the University of Rochester, New York and his Fellowship in Vascular & Interventional Radiology at Mallinckrodt Institute of radiology, Washington University, St. Louis. He practiced Interventional Radiology at the University of Rochester and University of Virginia, where he was the program director of the Vascular & Interventional Radiology Fellowship, before coming to the University of Michigan in 2013. Dr. Saad is active in the Society of Interventional Radiology (SIR) and was awarded the SIR-Fellowship in 2010. He served as the Chairman of the SIR Standards of Practice Committee from 2011 through to 2014.

  • Fibrates in the Context of Cholestatic Diseases

    Contains 1 Component(s) Recorded On: 06/09/2016

    Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on June 9, 2016.​

    Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on June 9, 2016.

    Olivier Barbier (Moderator)

    Carlo Spirli (Moderator)

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    David Assis